Daiichi Sankyo exon-skips into ultra-orphan ring with DMD alliance
This article was originally published in Scrip
Executive Summary
Perhaps encouraged by strong global investor and clinician interest in companies developing new drugs for very rare orphan diseases, Daiichi Sankyo has unveiled plans for a new Japanese joint venture specializing in antisense oligonucleotides for the treatment of Duchenne muscular dystrophy (DMD).
You may also be interested in...
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.
Takeda Sees Mainstays Tiding It Over Upcoming Expiries
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."